Member Info for LesBoy

Https://www.nytimes.com/2023/06/21/well/erectile-dysfunction-treatment-eroxon-gel.html

To approve for the period commencing twenty four (24) months following the date of this GM (Period), the

disapplication of the pre-emption provisions set out in Regulation 1.5 of the Company’s articles of association

in relation to the issue of, or the grant of any right to subscribe for or convert any security into, up to a further

five billion (5,000,000,000) ordinary shares, and to authorise the Directors of the Company to issue, or grant

any right to subscribe for or convert any security into, shares in accordance with the provisions of this

resolution, but so that the Company may make offers and enter into, agreements during the Period which

would, or might, require shares to be allotted or rights to subscribe for, or convert other securities into shares

to be granted after the Period ends

Good news for us?

More than 1,000 Pratt & Whitney engines are affected, forcing carriers to change schedules and ground craft.

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

https://www.ft.com/content/293fa80a-61a8-499b-bddd-c8c27accdf5d

Airlines in the US and Europe are rushing to find spare parts and engines and avoid flight cancellations after engine-maker Pratt & Whitney issued a product recall last month.

P&W’s announcement in July that more than a thousand engines would need to be removed from Airbus aircraft and inspected has forced a number of airlines — including Spirit Airlines, JetBlue Airways and Hawaiian Airlines in the US, and Wizz Air in Europe — to change flight schedules or ground aircraft.

Wizz has cut its growth target, is considering temporarily scrapping some flights or routes, and had warned that the engine problems are putting pressure on maintenance operations. Spirit told investors this month that with fewer aircraft to fly “we will likely be overstaffed” in the fourth quarter and early in 2024.

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

https://www.ft.com/content/293fa80a-61a8-499b-bddd-c8c27accdf5d

JetBlue chief operating officer Joanna Geraghty told investors this month that the company was looking to lease engines to minimise the fallout of removing “a handful” of engines from aircraft next month.

“We are trying to take whatever self-help measures are available,” she said. “But as you know, the supply is pretty constrained.”

P&W issued the recall after it discovered that contamination in the metal used to manufacture certain engine parts could cause cracks. Parent company RTX said that about 1,200 of the company’s 3,000 geared turbofan engines would need to be inspected earlier than planned. Roughly 200 of these inspections will take place by mid-September.

The GTF engine, which was introduced in 2016, is one of two that can be used in the Airbus A320neo narrow-body jet, the world’s best-selling aircraft. The recalls threaten RTX’s free cash flow, said Melius Research analyst Rob Spingarn, but “arguably worse is the damage to Pratt’s reputation as a provider of reliable large commercial engines”.

https://www.ft.com/content/293fa80a-61a8-499b-bddd-c8c27accdf5d

With Saudi men having up to four wives, the mind boggles at the sales potential there.

Forgive the pun.

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology, today announces that its distribution partner Labatec Pharma ("Labatec") has received regulatory approval for MED3000, Futura's innovative topical, gel-based Erectile Dysfunction ("ED") treatment, in the Kingdom of Saudi Arabia.

Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon®, with initial launch planned in Q4 2023. The manufacturing of Eroxon for the launch has been completed and it will be supported by a full marketing campaign. Saudi Arabia is one of the top ten ED markets in the world by value1, with a reported 10.45%2 of married males experiencing ED. Labatec will hold a launch symposium showcasing Eroxon at the 20th Urological Association of Asia Congress 2023, which is being held from 28 September to 1 October in conjunction with the 12th Emirates International Urological conference in Dubai, United Arab Emirates.

Futura is establishing a growing network of licencing and distribution partners and continues to strengthen its position, with regulatory approval having now been granted in six Middle Eastern countries, including the Kingdom of Saudi Arabia and the United Arab Emirates. Regulatory approval in the Kingdom of Saudi Arabia closely follows Futura's recent European and UK launch of Eroxon and the FDA's approval of MED3000 in the USA as the first clinically proven gel for the treatment of ED available without a doctor's prescription.

James Barder, Chief Executive Officer of Futura said: "Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market. Eroxon is a game changer in the ED space with its rapid speed of onset helping men get an erection within 10 minutes. This approval comes at a pivotal time for the Company, as we continue to grow and expand the availability of MED3000 globally by building out our licensing and distribution network."

Https://www.chronicle.co.zw/zimbabwe-bpoised-to-be-fifth-largest-lithium-producer/

Canadian Overseas Petroleum Limited (V9L.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

0.0330+0.0135 (+69.2308%)

https://finance.yahoo.com/quote/V9L.F?p=V9L.F&.tsrc=fin-srch

My apologies, Fin... I got it wrong!

... my apologies!

... in case it's slipped anyone's mind!

BAE reported profits of £1.23bn this morning and upped its dividend by 11 per cent year-on-year, as it continued to cash in on increased UK defence spending and soaring demand amid the war in Ukraine.

Britain’s premier defence contractor saw an order intake of £21.1bn, resulting in a record order backlog of £66.2bn. Revenues also shot up 11 per cent to £11bn, with top line sales growing by just under £1.5bn to £12bn year-on-year.

As a result, the firm – who manufacture submarines and fighter jets and a slew of other military vehicles – upgraded its guidance for 2023, forecasting higher sales and earnings per share of between 10 to 12 per cent, which it said reflected higher profits.

Charles Woodburn, BAE Systems Chief Executive, said: “We’ve delivered a strong financial performance in the first half of the year, thanks to the outstanding efforts of our employees.”

“With a record order backlog and good operational performance, we’re well positioned to continue delivering sustained growth in the coming years, giving us confidence to continue investing in new technologies, facilities, highly-skilled jobs and in our local communities.”

BAE said it had benefited from an “elevated global threat environment,” as Russia’s War in Ukraine and rising geopolitical uncertainty bumps up demand for weapons and defence systems.

Ascendant demand amid Putin’s war has ricocheted across the sector as a whole, with competitor Rolls-Royce seeing shares skyrocket 20 per cent last week after it doubled its profit guidance.

But the invasion of Ukraine has prompted not just a rise in demand, but also a shift in focus from the UK government, with many analysts forecasting a move to more production of weapons on home soil – to the benefit of companies’ like BAE.

That view is not without merit, based on the slew of recent lucrative contracts BAE have been awarded by the MoD.

Last month, the government handed BAE a £280m contract to boost the production of howitzer shells from UK factories.

In June, the company received a £270 million contract to manufacture radars for the Royal Navy, creating 400 high-skilled British jobs in the process.

https://www.cityam.com/war-what-is-it-good-for-bae-systems-announces-bumper-dividend/?utm_source=CityAM&utm_campaign=8cf2a6caa6-EMAIL_CAMPAIGN_2023_08_02_06_25&utm_medium=email&utm_term=0_-8cf2a6caa6-%5BLIST_EMAIL_ID%5D

£ 5,482,360 trade at 18:11

Hares in Newcrest Mining sunk 4.9 per cent on Friday morning after poor earnings reported by takeover bidder Newmont Corporation left analysts wanting.

Newcrest shares were trading at $26.26 each as at 10:17am after Newmont, which is taking over the Australian miner in a transaction valued at $29 billion, reported earnings that missed analyst estimates following a series of operational setbacks.

Its shares fell 6 per cent in New York for the biggest daily decline since July 2022.

Newmont’s second-quarter gold production dropped 17 per cent from a year earlier after it suspended the large Penasquito mine in Mexico due to a workers’ strike and reported weaker-than-expected performances from its Cerro Negro mine in Argentina and Akyem mine in Ghana.

It also temporarily shuttered a mine in Canada because of nearby wildfires.

Overall production costs rose to $1,472 an ounce, exceeding the average analyst estimate compiled by Bloomberg.

Shares in Newmont, which is working to close its acquisition of Newcrest Mining in the industry’s largest-ever deal, have tumbled 10 per cent this year, even as spot gold prices are up about 8 per cent.

The company reiterated its full-year forecasts on Thursday and said it expects a stronger second half.

https://thewest-com-au.cdn.ampproject.org/v/s/thewest.com.au/business/mining/newcrest-mining-shares-take-a-beating-as-newmont-corporation-shares-head-for-biggest-drop-in-a-year--c-11343304.amp?amp_gsa=1&_js_v=a9&usqp=mq331AQGsAEggAID#amp_tf=From%20%251%24s&aoh=16900015030936&csi=0&referrer=https%3A%2F%2Fwww.google.com&share=https%3A%2F%2Fthewest.com.au%2Fbusiness%2Fmining%2Fnewcrest-mining-shares-take-a-beating-as-newmont-corporation-shares-head-for-biggest-drop-in-a-year--c-11343304

Futura has made a new product that works, and it is only just starting to shout about it.

The company’s Eroxon gel is the first erectile dysfunction product approved to go on sale without a prescription. It is already available at Boots and online via the likes of Amazon, and it is the first new ED treatment for two decades. Clinical trials showed Eroxon successfully pumped up 65 per cent of users. Given the scale of the stigma-ridden, $3 billion (£2.3 billion) global market for men suffering a lack of erections — it is forecast to surpass $6 billion by 2032 — Futura looks appealing.

Rival treatments, such as Viagra and Cialis, both need a prescription and take longer to work: the Eroxon gel acts in ten minutes; it’s half an hour with rivals.

Futura has also minimised risk by outsourcing all it can: it does the science, but then, said chief executive James Barder, looks for “commercial partners to do the rest” — the marketing and distribution. “We’ve done so in the UK, Europe, and seven countries in the Middle East. Saudi [Arabia’s] approval is expected in September — that’s the biggest erectile dysfunction market in the Middle East — and we are working on a US partner .”

America has the world’s highest number of ED sufferers by far, and Barder said Futura had “interest from a number of parties”. Signing a commercial deal there would be likely to trigger a share price surge.

“The announcement of that US partner will be crucial as it’s very early days for Eroxon,” said Seb Jantet, an analyst at house broker Liberum. “But there are early signs of success.”

In the UK, where Futura’s product first hit Boots’s shelves exclusively in April, almost £2 million worth of Eroxon was sold in the first eight weeks, the firm told capital market day attendees last month. Its launch partner said it had been one of its most successful over-the-counter launches.

Futura is anticipating sales of £3 million this year — stocking orders from the small markets of the UK and Belgium. “These don’t really show the scale of what the product could do,” Jantet added. But Futura has more than £4 million in cash and a strong balance sheet. There are no guarantees of a happy ending, but it’s a worthy punt. Buy.

https://www.thetimes.co.uk/article/futura-is-looking-for-rapid-growth-8gpml9kzq

I wonder if there's a Nob B ?

... much appreciated.

Hi... I'm seeing really small trades of just a few hundred shares going through, which seems ludicrous to me, bearing in mind the trading cost involved. Could anyone explain this? Thanks.

7:02 PM BST, July 5, 2023:

HARARE, Zimbabwe (AP) — A Chinese mining company formally opened a $300 million lithium processing plant Wednesday in Zimbabwe, which has one of the world’s largest reserves of the metal as demand surges globally because of its use in electric car batteries.

Zimbabwe has the largest lithium reserves in Africa and has in recent years drawn investors in battery minerals from Canada, the United Kingdom and Australia, although China is the dominant player.

The plant opened by Prospect Lithium Zimbabwe, an arm of Chinese company Zhejiang Huayou Cobalt, has a capacity to process 4.5 million metric tons of hard rock lithium into concentrate for export per year, Zimbabwe President Emmerson Mnangagwa said.

Mnangagwa was present for the official opening of the sprawling plant in Goromonzi, about 80 kilometers (50 miles) southeast of Zimbabwe’s capital, Harare.

“Lithium is the mineral of the present and the future ... and value addition will position our country as an emerging and competitive player in the global lithium value chain,” Mnangagwa said. He urged the company to “beef” up expertise that would help Zimbabwe and other southern African countries “eventually” manufacture lithium batteries and other components locally.

Lithium is a key component for electric vehicle batteries. To cash in on demand, Zimbabwe last year banned the export of raw lithium ore. In doing so, it joined countries like Indonesia and Chile that are trying to maximize their return on deposits of lithium, cobalt and nickel by requiring miners to invest locally in refining and processing before they can export.

Prospect Lithium Zimbabwe deputy general manager Trevor Barnard said that the firm aims to start by processing 450,000 tons of concentrate every year. The concentrate will be further processed into battery-grade lithium outside Zimbabwe.

https://apnews.com/article/lithium-processing-plant-chinese-92ccd10bd4ba028bc38fdadcdffc06da

The changes feed into MGC Pharmaceuticals’ goal to become a significant player in the pioneering field of psychedelic research and development. This aim was further strengthened when, on April this year, the company received approval from the Slovenian Ministry of Health for scientific research developments related to Psilocybin.

As a result of these regulatory advancements, MGC can now provide accurate, pharmaceutical-grade products, reinforcing its commitment to meeting stringent industry standards. Furthermore, the company intends to leverage its existing distribution channels to increase Psilocybin sales in Australia, aiming to provide this treatment option to patients in need.